Trending...
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- Digi 995: Warbot Run Officially Launches on the Apple App Store
CHICAGO, Oct. 31, 2024 ~ Amphix Bio, a leading company in the development of regenerative medicine therapies, has announced that it has been awarded a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF). The grant will be used to scale up manufacturing methods for the company's innovative platform technology, which is based on supramolecular peptide therapeutics that signal the patient's own cells to initiate regenerative processes.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Kanoa Debuts Gluten-Free Filled Cereals, Delivering Bold Flavor & Better Nutrition for Anytime Snac
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- National Van Lines Delivers Holiday Cheer with Aspire Partnership
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
Filed Under: Business
0 Comments
Latest on illi News
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Holiday Pond Lighting Ideas for Chicago-Area Water Features
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Illinois 45th District Candidate Josh Atkinson Introduces a New Way to Reach Voters
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- Naperville: Drive Sober or Get Pulled Over This Season
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- Fintravion Business Academy(FBA)Under Adrian T. Langshore Advances FintrionAI 6.0 Architecture
- Bensenville cleaning company offers free home cleaning for cancer patients
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention